These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 39380002)

  • 1. The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency.
    Sheridan M; Maqbool MA; Largeot A; Clayfield L; Xu J; Moncaut N; Sellers R; Whittle J; Paggetti J; Iqbal M; Aucagne R; Delva L; Baker SM; Lie-A-Ling M; Kouskoff V; Lacaud G
    J Hematol Oncol; 2024 Oct; 17(1):91. PubMed ID: 39380002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia.
    Al-Kershi S; Bhayadia R; Ng M; Verboon L; Emmrich S; Gack L; Schwarzer A; Strowig T; Heckl D; Klusmann JH
    Blood Adv; 2019 Dec; 3(24):4252-4263. PubMed ID: 31867596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
    Marneth AE; Prange KHM; Al Hinai ASA; Bergevoet SM; Tesi N; Janssen-Megens EM; Kim B; Sharifi N; Yaspo ML; Kuster J; Sanders MA; Stoetman ECG; Knijnenburg J; Arentsen-Peters TCJM; Zwaan CM; Stunnenberg HG; van den Heuvel-Eibrink MM; Haferlach T; Fornerod M; Jansen JH; Valk PJM; van der Reijden BA; Martens JHA
    Leukemia; 2018 Mar; 32(3):828-836. PubMed ID: 28871137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in
    Adriaanse FRS; Schneider P; Arentsen-Peters STCJM; Fonseca AMND; Stutterheim J; Pieters R; Zwaan CM; Stam RW
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
    Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
    Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
    Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
    Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.
    Vetro C; Haferlach T; Meggendorfer M; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2020 Jan; 240():15-22. PubMed ID: 31698332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent
    Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
    Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
    Ikeda J; Shiba N; Tsujimoto SI; Yoshida M; Nakabayashi K; Ogata-Kawata H; Okamura K; Takeuchi M; Osumi T; Tomizawa D; Hata K; Kiyokawa N; Ito S; Kato M
    Genes Chromosomes Cancer; 2019 Sep; 58(9):669-672. PubMed ID: 30869817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
    Kwon MC; Thuring JW; Querolle O; Dai X; Verhulst T; Pande V; Marien A; Goffin D; Wenge DV; Yue H; Cutler JA; Jin C; Perner F; Hogeling SM; Shaffer PL; Jacobs F; Vinken P; Cai W; Keersmaekers V; Eyassu F; Bhogal B; Verstraeten K; El Ashkar S; Perry JA; Jayaguru P; Barreyro L; Kuchnio A; Darville N; Krosky D; Urbanietz G; Verbist B; Edwards JP; Cowley GS; Kirkpatrick R; Steele R; Ferrante L; Guttke C; Daskalakis N; Pietsch EC; Wilson DM; Attar R; Elsayed Y; Fischer ES; Schuringa JJ; Armstrong SA; Packman K; Philippar U
    Blood; 2024 Sep; 144(11):1206-1220. PubMed ID: 38905635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy-induced Deletion in 11q23 Leading to Fusion of
    Panagopoulos I; Andersen K; Eilert-Olsen M; Zeller B; Munthe-Kaas MC; Buechner J; Osnes LTN; Micci F; Heim S
    Cancer Genomics Proteomics; 2021; 18(1):67-81. PubMed ID: 33419897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in
    Wang H; Shah CA; Hu L; Huang W; Platanias LC; Eklund EA
    J Biol Chem; 2020 Jul; 295(28):9663-9675. PubMed ID: 32467231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
    Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
    Nguyen D; Kantarjian HM; Short NJ; Qiao W; Ning J; Cuglievan B; Daver NG; DiNardo CD; Jabbour EJ; Kadia TM; Borthakur G; Garcia-Manero G; Konopleva MY; Andreeff M; Ravandi-Kashani F; Sasaki K; Issa GC
    Cancer; 2023 Jun; 129(12):1856-1865. PubMed ID: 36892949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia.
    Yin L; Wan L; Zhang Y; Hua S; Shao X
    Cancer Med; 2024 Oct; 13(20):e70326. PubMed ID: 39428967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia.
    Verbeek TCAI; Vrenken KS; Arentsen-Peters STCJM; Castro PG; van de Ven M; van Tellingen O; Pieters R; Stam RW
    Commun Biol; 2024 Oct; 7(1):1257. PubMed ID: 39362994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.
    Issa GC; Zarka J; Sasaki K; Qiao W; Pak D; Ning J; Short NJ; Haddad F; Tang Z; Patel KP; Cuglievan B; Daver N; DiNardo CD; Jabbour E; Kadia T; Borthakur G; Garcia-Manero G; Konopleva M; Andreeff M; Kantarjian HM; Ravandi F
    Blood Cancer J; 2021 Sep; 11(9):162. PubMed ID: 34588432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.